The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).
 
Koral Shah
No Relationships to Disclose
 
Aravinda Ganapathy
No Relationships to Disclose
 
Ariel Borkowski
No Relationships to Disclose
 
Nakul Shah
No Relationships to Disclose
 
Dhruv Bansal
No Relationships to Disclose
 
Rachel Beck
No Relationships to Disclose
 
Eric Marshall Knoche
Stock and Other Ownership Interests - Bristol-Myers Squibb/Pfizer (I); Cardiff Oncology; Exelixis; Gilead Sciences (I); Johnson & Johnson/Janssen (I); Karyopharm Therapeutics; Merck (I); Roche/Genentech (I)
 
Joel Picus
Consulting or Advisory Role - Pfizer
Research Funding - BioClin Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Mirati Therapeutics (Inst); Seagen (Inst); TRACON Pharma (Inst)
 
Melissa Andrea Reimers
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Pfizer (Inst); FORMA Therapeutics (Inst)
 
Bruce J. Roth
Consulting or Advisory Role - Merck; Seagen
Research Funding - Medivation (Inst)
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje
 
Robert Schreiber
Employment - Washington University School of Medicine
Stock and Other Ownership Interests - A2 Biotherapeutics; Arch Oncology; Asher Biotherapeutics; BioNTech; Jounce Therapeutics; NGM Biopharmaceuticals; Sensei Biotherapeutics
Consulting or Advisory Role - Asher Biotherapeutics; Codiak Biosciences; Jounce Therapeutics; NGM Biopharmaceuticals; Sensei Biotherapeutics
Research Funding - Centene; Janssen; Jounce Therapeutics; Parker Institute for Cancer Immunotherapy
Patents, Royalties, Other Intellectual Property - Washington University School of Medicine
Travel, Accommodations, Expenses - Society for Immunotherapy of Cancer
 
Russell Kent Pachynski
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Jounce Therapeutics; Pfizer/EMD Serono; Sanofi
Speakers' Bureau - AstraZeneca; Dendreon; Genentech/Roche; Genomic Health; Merck; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Janssen Oncology; Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Entitled: METHOD OF CELL-FREE DNA ANALYSIS TO IDENTIFY HIGH-RISK METASTATIC PROSTATE CANCER
Travel, Accommodations, Expenses - Genentech/Roche